Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Ad Policies Will Be One Issue In Commissioner Confirmation Process

Executive Summary

FDA's reconsideration of its authority to regulate drug promotions under the First Amendment is one issue FDA Commissioner nominee Mark McClellan is likely to face during Senate confirmation hearings
Advertisement

Related Content

RU-486 safety profile
RU-486 safety profile
DTC Is Not Improving, Rep. Waxman Says: Viagra Ads Show “Six” Sells?
DTC Is Not Improving, Rep. Waxman Says: Viagra Ads Show “Six” Sells?
FDA Needs Five Centers, Crawford Says; CBER Centennial Is Emotional Affair
FDA Press Release Policy Restricts Free Speech, Needs Revision – PhRMA
CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16
FDA Seeks Comment On Ad Regs: Can Rx Be More Regulated Than OTCs?
FDA Seeks Comment On Ad Regs: Can Rx Be More Regulated Than OTCs?
FDA's Schwetz Is Acting Commissioner: RU-486 Appears To Be Touchstone
Advertisement
UsernamePublicRestriction

Register

PS040539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel